Effects of Intraperitoneal Administration of Mifepristone on Glucocorticoid Status of Experimental Animals


Citar

Texto integral

Acesso aberto Acesso aberto
Acesso é fechado Acesso está concedido
Acesso é fechado Somente assinantes

Resumo

We studied the content of corticosterone and its precursors in the adrenal glands, corticosterone in blood serum and daily urine of rats, and activity of first and second isoforms of 11β-hydroxysteroid dehydrogenase in the liver and kidneys of rats after 15 daily intraperitoneal injections of 0.9% NaCl or glucocorticoid receptor blocker mifepristone in 0.9% NaCl. Daily injections of NaCl reduced the levels of pregnenolone, progesterone, and corticosterone in the adrenal glands, increased corticosterone excretion with urine, enhanced activity of the first isoform of 11β-hydroxysteroid dehydrogenase in the liver and reduction in activity of the second isoform of this enzyme in the kidneys. These changes are typical manifestations of chronic stress. Mifepristone restored pregnenolone content in the adrenal glands and increase in corticosterone concentration in the blood. Under these conditions, activity of the first isoform of 11β-hydroxysteroid dehydrogenase in the liver did not change, and a decrease in activity of the second isoform of the enzyme in the kidneys was less pronounced. The results suggest that mifepristone abolished the stress-mediated increase in activity of the first isoform of 11β-hydroxysteroid dehydrogenase in the liver and reduced local production of glucocorticoid hormones and their metabolic effects in hepatocytes.

Sobre autores

N. Pal’chikova

Institute of Experimental and Clinical Medicine

Autor responsável pela correspondência
Email: labend@centercem.ru
Rússia, Novosibirsk

N. Kuznetsova

Institute of Experimental and Clinical Medicine

Email: labend@centercem.ru
Rússia, Novosibirsk

V. Selyatitskaya

Institute of Experimental and Clinical Medicine

Email: labend@centercem.ru
Rússia, Novosibirsk

O. Cherkasova

Institute of Experimental and Clinical Medicine

Email: labend@centercem.ru
Rússia, Novosibirsk

O. Kuz’mina

Institute of Experimental and Clinical Medicine

Email: labend@centercem.ru
Rússia, Novosibirsk


Declaração de direitos autorais © Springer Science+Business Media New York, 2016

Este site utiliza cookies

Ao continuar usando nosso site, você concorda com o procedimento de cookies que mantêm o site funcionando normalmente.

Informação sobre cookies